Value of IFNL3 genetic polymorphism in the prediction of HCV treatment response to direct-acting antiviral drugs versus interferon therapy

References

• Waked I, Esmat G, Elsharkawy a, et al. Screening and treatment program to eliminate Hepatitis C in Egypt. N Engl J Med. 2020;382:12.
   Web of Science ®Google Scholar
• Tsubota a, Fujise K, Namiki Y, et al. Peginterferon and ribavirin treatment for hepatitis C virus infection. World J Gastroenterol. 2011;17(4):419–432.
   PubMed Web of Science ®Google Scholar
• Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut. 2006;55(9):1350–1359.
   PubMed Web of Science ®Google Scholar
• Asselah T, Boyer N, Saadoun D, et al. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int. 2016;36(Suppl 1):47–57.
   PubMed Web of Science ®Google Scholar
• Arias a, Aguilera a, Soriano V, et al. Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials. Antivir Ther. 2017;22(4):307–312.
   PubMed Web of Science ®Google Scholar
• Buti M, Riveiro-Barciela M, Esteban R. Management of direct antiviral agent failures. J Hepatol. 2015;63:1511–1522.
   PubMed Web of Science ®Google Scholar
• Benítez-Gutiérrez L, Barreiro P, Labargap, et al. Prevention and management of treatment failure to new oral hepatitis C drugs. Expert Opin Pharmacother. 2016;17(9):1215: 23.
   Web of Science ®Google Scholar
• Lontok E, Harrington P, Howe a, et al. Hepatitis C virus drug resistance-associated substitutions: state of the art summary. Hepatology. 2015;62:1623–1632.
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology. 2016);151(1):70e86.
   Web of Science ®Google Scholar
• Liu T, Sha K, Yang L, et al. IL-28B polymorphisms correlated with treatment response in HCV-4 mono-infected patients: a meta-analysis. PLoS ONE. 2014;9(3):e91316.
   PubMed Web of Science ®Google Scholar
• Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461(7265):798‐801.
   PubMed Web of Science ®Google Scholar
• Wack a, Terczyńska-Dyla E, Hartmann R. Guarding the frontiers: the biology of type III interferons. Nat Immunol. 2015;16(8):802–809.
   PubMed Web of Science ®Google Scholar
• Stattermayer AF, Strassl R, Maieron a, et al. Polymorphisms of interferon-lambda4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2014;39(1):104–111.
   PubMed Web of Science ®Google Scholar
• Elgharably a, Gomaa AI, Crossey MM, et al. Hepatitis C in Egypt - past, present, and future. Int J Gen Med. 2016;10:1–6.
   PubMed Web of Science ®Google Scholar
• Zidan H, Talaat R, Ammar a, et al. Interleukin 28B polymorphism as a predictor of response to treatment of Egyptian HCV patients working in nuclear material authority. Egypt J Hosp Med. 2019;77(1):4742–4747.
   Google Scholar
• Asselah T, De Muynck S, Broet P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol. 2011;56:527‐ 32.
   Google Scholar
• Ghany MG, nelson DR, Strader DB, et al. American Linkage for Study of Liver D. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Linkage for the Study of Liver Diseases. Hepatology. 2011;54(4):1433–1444.
   PubMed Web of Science ®Google Scholar
• European Linkage for the Study of the liver diseases. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55(2):245–264.
   PubMed Web of Science ®Google Scholar
• Machicote a, Flichmann D, Arana E, et al. IL28B SNPs rs12979860 and rs8099917 are associated with inflammatory response in Argentine chronic HCV patients. Int J Clin Med. 2019;09(2):79e91.
   Google Scholar
• Centre for Disease Control and Prevention. Morbidity and Mortality Weekly Report (MMWR). MMWR/. 61/. 29; 2012.
   Google Scholar
• Kandeel a, Genedy M, El‐Refai S, et al. The prevalence of hepatitis C virus infection in Egypt: implications for future policy on prevention and treatment. Liver Int. 2015;37:45–53.
   Web of Science ®Google Scholar
• Petta S, Craxı` a. Therapeutic algorithms for chronic hepatitis C in the DAA era during the current economic crisis: whom to treat? How to treat? When to treat? BMC Infect Dis. 2012;12(Suppl 2):S3.
   PubMedGoogle Scholar
• Pedergnana V, Abdel-Hamid M, Guergnon J, et al. Analysis of IL28B variants in an Egyptian population defines the 20 kilobases minimal region involved in spontaneous clearance of Hepatitis C virus. PLoS One. 2012;7(6):e38578.
   PubMed Web of Science ®Google Scholar
• Sakhaeea F, Ghazanfaria M, Vaziriab F, et al. The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection. Infect Genet Evol. 2017;54:330–337.
   PubMed Web of Science ®Google Scholar
• Sedighimehr P, Irani S, Sakhaee F, et al. IL28B rs12980275 and HLA rs4273729 genotypes as a powerful predictor factor for rapid, early, and sustained virologic response in patients with chronic hepatitis C. Arch Virol. 2017;162:181–189.
   PubMed Web of Science ®Google Scholar
• Asnavandi M, Zargar M, Vaziri F, et al. EGFR rs11506105 and IFNL3 SNPs but not rs8099917 are strongly associated with treatment responses in Iranian patients with chronic hepatitis C. Genes Immun. 2017;18(3):144–151.
   PubMed Web of Science ®Google Scholar
• El-Awady M, Mostafa L, Tabll a, et al. Linkage of IL28B SNP with progression of Egyptian HCV genotype 4 patients to end stage liver disease. Hepat Mon. 2012;12(4):271–277. Online ahead of Print.
   PubMed Web of Science ®Google Scholar
• Esmail M, Hassuna N, Amr K, et al. Polymorphisms at IL28B gene as predictors of viral relapse in genotype 4 Egyptian hepatitis C patients. J Med Virol. 2016;88(3):481–486.
   PubMed Web of Science ®Google Scholar
• Khan a, Saraswat V, Ranjan P, et al. Polymorphism in interferon λ3/interleukin‐28B gene and risk to noncirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy. J Med Virol. 2012;91:659–667.
   Google Scholar
• Obada M, El-Fert a, Morad W, et al. Impact of IL28B polymorphism on treatment induced viral clearance in HCV infected Egyptian patients. Egypt J Biochem Mol Biol. 2014;32:172–189.
   Google Scholar
• Sporea I, popescu a, Curescu M, et al. The correlation of Il28B genotype with sustained virologic response in Romanian patients with chronic Hepatitis C. Hepat Mon. 2012;11(12):956–957.
   Web of Science ®Google Scholar
• Attallah AM, Omran D, Omran MM, et al. Extracellular matrix proteins substantiate il-28b t allele effect on histological outcome of chronic hepatitis C. Ann Hepatol. 2018;17(4):569–576.
   PubMed Web of Science ®Google Scholar
• Hendy O, Abd El Moneam E, Al Shafie M, et al. Role of IL28B gene polymorphisms in response to the standard of care treatment in Egyptian patients with chronic HCV genotype 4. Life Sci J. 2011;8:908–915.
   Google Scholar
• Khairy M, Fouad R, Mabrouk M, et al. The impact of interleukin 28b gene polymorphism on the virological response to combined pegylated interferon and ribavirin therapy in chronic HCV genotype 4 infected Egyptian patients using data mining analysis. Hepat Mon. 2013;13:7.
   Web of Science ®Google Scholar
• Par a, Kisfali P, Melegh B, et al. Cytokine (IL-10, IL-28B and LT-a) gene polymorphisms in chronic hepatitis C virus infection. Clin Exp Med. 2011;5:9–19.
   Google Scholar
• Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401.
   PubMed Web of Science ®Google Scholar
• Mechie NC, Röver C, Cameron S, et al. Predictability of IL-28Bpolymorphism on protease-inhibitor-based triple-therapy in chronic HCVgenotype-1 patients: a meta-analysis. World J Hepatol. 2014;6(10):759-765
   PubMedGoogle Scholar
• Mangia a, Thompson AJ, Santoro R, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology. 2010;139:821–827.
   PubMed Web of Science ®Google Scholar
• Bronowicki J-P, Hezode C, Bengtsson L. 100% Svr In Il28b Cc patients treated with 12 weeks of telaprevir, peginterferon and ribavirin in the prove2 trial. J Hepatol. 2012;56:S430–S431.
   Web of Science ®Google Scholar
• Tsuchiya M, Parker JS, Kono H, et al. Gene expression in nontumoral liver tissue and recurrence-free survival in hepatitis C virus-positive hepatocellular carcinoma. Mol Cancer. 2010;9:74.
   PubMed Web of Science ®Google Scholar
• Reig M, Mariño Z, Perello C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65(4):719–726.
   PubMed Web of Science ®Google Scholar
• Calvaruso V, Cabibbo G, Cacciola I, et al. Occurrence of hepatocellular carcinoma in patients with hepatitis C virus related liver disease treated with direct-acting antivirals. J Hepatol. 2017;66(1):S23–S24.
   Web of Science ®Google Scholar
• Spârchez Z, Mocan T. Hepatocellular carcinoma occurrence and recurrence after anti-viral treatment in HCV-related . are outcomes different after direct antiviral agents? A review cirrhosis. J Gastrointestin Liver Dis. 2017;26(4):403–410.
   PubMed Web of Science ®Google Scholar